A revolutionary oncology company, targeting tumours through unique technologies.
Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies. Operating from Manchester, with research facilities in Bradford and Salford, Incanthera Ltd was established from the University of Bradford’s Institute of Cancer Therapeutics (www.cancer.brad.ac.uk).
Incanthera is uniquely positioned to access commercially valuable patent estates and development programmes, initially from the Institute, but with a wider horizon for pipeline acquisition. The first product, and primary focus has been to bring ICT2588, a novel treatment for solid tumours, to a licensing partner. This was successfully achieved through our first commercial deal, announced in July 2017, bringing the product to Phase I clinical trial in early 2018.
The provenance of Incanthera’s pipeline includes a number of UK Universities and, consequently, a heritage of world-leading scientific drug discovery. The Company, through its careful positioning, is able to bridge the perceived funding gap that otherwise prevents great research from translating into commercially successful products and the delivery of those much needed treatments for serious diseases.
The company and its projects have previously been funded through research grants from CRUK (Cancer Research UK), YCR (Yorkshire Cancer Research), the University of Bradford and equity investment from the North West Fund for Biomedical, managed by SPARK Impact Ltd (SPARK), a UK Venture Capital company, alongside Advent International and investment from private individuals (Business Angels).